Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GB:0QYQ)
LSE:0QYQ
Gilead Sciences (0QYQ) Share Price & Analysis
1 Followers
0QYQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$66.95 - $86.64
Previous Close$67.26
Volume5.37K
Average Volume (3M)51.61K
Market Cap
$83.46B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.9
Beta0.63
Next Earnings
Apr 25, 2024EPS Estimate
$1.57Last Dividend Ex-Date
Mar 14, 2024Dividend Yield4.49%
Share Statistics
EPS (TTM)4.50
Shares Outstanding1,245,774,616
10 Day Avg. Volume14,408
30 Day Avg. Volume51,611
Standard Deviation0.07
R-Squared0.00951
Alpha-0.00337
Financial Highlights & Ratios
Price to Book (P/B)-7.03
Price to Sales (P/S)3.00
Price to Cash Flow (P/CF)9.70
P/FCF Ratio9.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$85.89Price Target Upside27.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company's HIV business remains extremely well positioned and durable, with no patent expirations on the horizon, Biktarvy continuing to gain share, and the lenacapavir opportunity still underappreciated.
Oncology GrowthIn oncology, the CART franchise is gaining scale and Trodelvy is expanding into a number of indications over time, representing an important growth driver for the company.
Operational EfficiencyImprovements in median U.S. turnaround time for Yescarta to 14 days with a 96% success rate demonstrate operational efficiency.
Bears Say
Clinical SetbacksRecent oncology setbacks, including EVOKE-01 miss and ARC-10 study discontinuation, may erode investor confidence in the company's pipeline.
Financial PerformanceGuidance for 2024 is just a tad light on revenues, reflecting underlying weakness in product sales.
Intellectual Property ConcernsIntellectual property concerns may arise as core composition of matter patents for Seladelpar are expiring soon, raising questions on long-term exclusivity.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.90% Insiders
30.69% Mutual Funds
26.65% Other Institutional Investors
41.76% Public Companies and
Individual Investors
0QYQ FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest share price was $66.95 and its highest was $86.64 in the past 12 months.
What is Gilead Sciences’s market cap?
Currently, no data Available
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Apr 25, 2024 which is in 6 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Feb 06, 2024. The company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.758 by -$0.038.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 4.49%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is $1.57.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,246,969,400 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $1.72 in its last earnings report, missing expectations of $1.758. Following the earnings report the stock price went down -3.459%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 3B.
---
Gilead Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$85.89 (27.70% Upside)
$85.89 (27.70% Upside)
Blogger Sentiment
Bullish
GB:0QYQ Sentiment 93%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.81%
12-Months-Change
Fundamentals
Return on Equity
25.71%
Trailing 12-Months
Asset Growth
-1.66%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
0QYQ Company Deck
---
0QYQ Earnings Call
Q4 2024
0:00 / 0:00
---
0QYQ Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
0QYQ Stock 12 Months Forecast
Average Price Target
$85.89
▲(27.70% Upside)
Technical Analysis
Best Analysts Covering 0QYQ
1 Year
1 Year Success Rate
31/57 ratings generated profit
1 Year Average Return
+5.71%
reiterated a buy rating last month
Copying Salim Syed's trades and holding each position for 1 Year would result in 54.39% of your transactions generating a profit, with an average return of +5.71% per trade.
---